The Anorexia Nervosa Market to Grow Positively at a Massive CAGR of 18.9% During the Study Period (2019–2032), Assesses DelveInsight

Nevada (Las Vegas), United States, DelveInsight’s “Anorexia Nervosa – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Anorexia Nervosa market share of the individual therapies, current and forecasted Anorexia Nervosa market size from 2019 to 2032 segmented by seven major markets. The report also offers current Anorexia Nervosa therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Anorexia Nervosa market.

Anorexia Nervosa Overview
Anorexia Nervosa is a type of eating disorder marked by weight loss (or failure to gain weight in growing children), difficulty maintaining a healthy body weight for one’s height, age, and stature, and, in many cases, a distorted body image. Anorexics frequently limit their calorie intake and the types of foods they consume. The precise causes of Anorexia Nervosa are unknown. Genetic risk factors, as well as a combination of environmental, social, and cultural factors, may all play a role. Certain personality traits may make some people more susceptible to anorexia than others.

Malnutrition is linked to the physical symptoms of Anorexia Nervosa. Anorexia also includes mental and behavioral disorders such as an inaccurate perception of one’s own body weight and an intense fear of gaining weight or becoming obese. Anorexia Nervosa symptoms can be difficult to detect because what constitutes a low body weight varies from person to person, and some people may not appear particularly thin. Furthermore, people suffering from anorexia frequently conceal their thinness, eating habits, or health problems. Physical exams, lab tests, psychological evaluation, X-ray, ECG, and other tests are used to diagnose Anorexia Nervosa.

Anorexia Nervosa Epidemiological Insights
The Anorexia Nervosa epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by prevalent cases, diagnosed prevalent cases, and gender-specific prevalence in the 7MM market covering the United States, EU-4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan from 2019 to 2032.

As per DelveInsight, the total Anorexia Nervosa prevalent cases were approx 1.6 million cases in the 7MM in 2021. Among EU5 countries, Germany has the highest Anorexia Nervosa diagnosed prevalence, while Spain had the lowest in 2021.

Anorexia Nervosa Treatment Market
Treatment usually consists of a combination of techniques, such as psychiatric therapy, dietary counseling, and hospitalization. Psychotherapies include family-based treatment (FBT), eating disorder-focused psychotherapy, adolescent-focused psychotherapy, and others. Antidepressants, antipsychotics, and mood stabilizers may be useful in the treatment of eating disorders as well as other co-occurring conditions such as anxiety or depression. Treatment for Anorexia Nervosa must address both psychological and physical issues. The therapy team should include a mental health expert and a primary care physician.

Promising Therapies in the Anorexia Nervosa Pipeline
• Psilocybin
• RQ 00433412
• ART 2713
• PF-07258669
• Ketamine

Discover more about Anorexia Nervosa therapies in the pipeline @ Anorexia Nervosa Drugs

Leading Companies Working in the Anorexia Nervosa Market
• COMPASS Pathways
• Benuvia Therapeutics
• Artelo Biosciences
• RaQualia Pharma
• Receptor Life Sciences
• AstraZeneca
• Pfizer
• Homeostasis Therapeutics, LLC

Learn more about the recent developments and breakthroughs in the Anorexia Nervosa market @ Anorexia Nervosa Clinical Trials

Anorexia Nervosa Market Dynamics
The rising prevalence of Anorexia Nervosa and the growing number of cases worldwide are expected to lead to more treatment options. As a result, the Anorexia Nervosa market will grow in the coming year. Furthermore, because most guideline recommendations encourage the use of drug therapy in conjunction with psychotherapies, drug development companies can create novel treatment packages that include both drugs and psychotherapies, boosting the Anorexia Nervosa market even further.

As per DelveInsight’s estimates, the Anorexia Nervosa market size was USD 63 million in 2021 which is further expected to increase by 2032 in the 7MM.

However, certain factors are impeding the growth of the Anorexia Nervosa market. One of the primary reasons is a lack of trainers or experts to speak with patients and raise public awareness about Anorexia Nervosa.

Scope of the Anorexia Nervosa Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]
Key Anorexia Nervosa Companies: COMPASS Pathways, Benuvia Therapeutics, Artelo Biosciences, RaQualia Pharma, Receptor Life Sciences, AstraZeneca, Pfizer, Homeostasis Therapeutics, LLC, and others
Key Anorexia Nervosa Pipeline Therapies: Psilocybin, RQ 00433412, ART 2713, PF-07258669, Ketamine, and others
Therapeutic Assessment: Anorexia Nervosa current marketed and emerging therapies
Anorexia Nervosa Market Dynamics: Anorexia Nervosa market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Anorexia Nervosa Market Access and Reimbursement

Table of Contents
1. Anorexia Nervosa Market Key Insights
2. Anorexia Nervosa Market Report Introduction
3. Anorexia Nervosa Market Overview at a Glance
4. Anorexia Nervosa Market Executive Summary
5. Disease Background and Overview
6. Anorexia Nervosa Treatment and Management
7. Anorexia Nervosa Epidemiology and Patient Population
8. Patient Journey
9. Anorexia Nervosa Emerging Drugs
10. 7MM Anorexia Nervosa Market Analysis
11. Anorexia Nervosa Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Anorexia Nervosa Market Drivers
15. Anorexia Nervosa Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187